Inventiva Submits 2025 Financial Reports to AMF and SEC

Inventiva, a clinical-stage biopharmaceutical firm, announced the submission of its 2025 Universal Registration Document and Annual Report on Form 20-F. These documents cover the fiscal year ending December 31, 2025. The Universal Registration Document was filed with the French Autorité des Marchés Financiers (AMF), while the Form 20-F was submitted to the U.S. Securities and Exchange Commission (SEC).

The company specializes in developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH). Interested parties can find these documents on Inventiva’s website, along with the AMF and SEC’s official sites for further insights.